These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 10751589)

  • 1. Relapse and cure rates of prostate cancer patients after radical prostatectomy and 5 years of follow-up.
    Vassilikos EJ; Yu H; Trachtenberg J; Nam RK; Narod SA; Bromberg IL; Diamandis EP
    Clin Biochem; 2000 Mar; 33(2):115-23. PubMed ID: 10751589
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stage T1-2 prostate cancer: a multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy.
    Kupelian PA; Katcher J; Levin HS; Klein EA
    Int J Radiat Oncol Biol Phys; 1997 Mar; 37(5):1043-52. PubMed ID: 9169811
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlation of clinical and pathologic factors with rising prostate-specific antigen profiles after radical prostatectomy alone for clinically localized prostate cancer.
    Kupelian P; Katcher J; Levin H; Zippe C; Klein E
    Urology; 1996 Aug; 48(2):249-60. PubMed ID: 8753737
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ultrasensitive detection of prostate specific antigen in the followup of 422 patients after radical prostatectomy.
    Haese A; Huland E; Graefen M; Hammerer P; Noldus J; Huland H
    J Urol; 1999 Apr; 161(4):1206-11. PubMed ID: 10081870
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Margin details matter: The prognostic significance of pseudocapsule invasion at the site of involved margin in prostatectomy specimens.
    Russo JK; Laszewski M; Rodacker M; Watkins PL; Dufan TA; Koleilat N; Watkins JM
    Urol Oncol; 2015 Sep; 33(9):383.e1-7. PubMed ID: 26097050
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.
    Ploussard G; Agamy MA; Alenda O; Allory Y; Mouracade P; Vordos D; Hoznek A; Abbou CC; de la Taille A; Salomon L
    BJU Int; 2011 Jun; 107(11):1748-54. PubMed ID: 20883488
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Usefulness of postoperative nadir prostate-specific antigen value by ultrasensitive assay as a predictor of prostate-specific antigen relapse for pathological T3 or positive surgical margins after radical prostatectomy for prostate cancer.
    Yoshida T; Matsuzaki K; Kobayashi Y; Takeda K; Nakayama M; Arai Y; Kakimoto K; Nishimura K
    Int Urol Nephrol; 2012 Apr; 44(2):479-85. PubMed ID: 21822599
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ultrasensitive serum prostate specific antigen nadir accurately predicts the risk of early relapse after radical prostatectomy.
    Shen S; Lepor H; Yaffee R; Taneja SS
    J Urol; 2005 Mar; 173(3):777-80. PubMed ID: 15711268
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer.
    Roberts SG; Blute ML; Bergstralh EJ; Slezak JM; Zincke H
    Mayo Clin Proc; 2001 Jun; 76(6):576-81. PubMed ID: 11393495
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early detection of residual prostate cancer after radical prostatectomy by an ultrasensitive assay for prostate specific antigen.
    Stamey TA; Graves HC; Wehner N; Ferrari M; Freiha FS
    J Urol; 1993 Apr; 149(4):787-92. PubMed ID: 7681119
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detection of prostate cancer relapse with prostate specific antigen monitoring at levels of 0.001 to 0.1 microG./L.
    Yu H; Diamandis EP; Wong PY; Nam R; Trachtenberg J
    J Urol; 1997 Mar; 157(3):913-8. PubMed ID: 9072598
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Seminal vesicle involvement after radical prostatectomy: predicting risk factors for progression.
    Salomon L; Anastasiadis AG; Johnson CW; McKiernan JM; Goluboff ET; Abbou CC; Olsson CA; Benson MC
    Urology; 2003 Aug; 62(2):304-9. PubMed ID: 12893340
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early prostate-specific antigen relapse after radical retropubic prostatectomy: prediction on the basis of preoperative and postoperative tumor characteristics.
    Graefen M; Noldus J; Pichlmeier U; Haese A; Hammerer P; Fernandez S; Conrad S; Henke R; Huland E; Huland H
    Eur Urol; 1999; 36(1):21-30. PubMed ID: 10364651
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Usefulness of the nadir value of serum prostate-specific antigen measured by an ultrasensitive assay as a predictor of biochemical recurrence after radical prostatectomy for clinically localized prostate cancer.
    Sakai I; Harada K; Kurahashi T; Muramaki M; Yamanaka K; Hara I; Inoue TA; Miyake H
    Urol Int; 2006; 76(3):227-31. PubMed ID: 16601384
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The relationship between the extent of surgical margin positivity and prostate specific antigen recurrence in radical prostatectomy specimens.
    Marks RA; Koch MO; Lopez-Beltran A; Montironi R; Juliar BE; Cheng L
    Hum Pathol; 2007 Aug; 38(8):1207-11. PubMed ID: 17490720
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sensitive prostate specific antigen measurements identify men with long disease-free intervals and differentiate aggressive from indolent cancer recurrences within 2 years after radical prostatectomy.
    Witherspoon LR; Lapeyrolerie T
    J Urol; 1997 Apr; 157(4):1322-8. PubMed ID: 9120931
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Three-year postoperative ultrasensitive prostate-specific antigen following open radical retropubic prostatectomy is a predictor for delayed biochemical recurrence.
    Malik RD; Goldberg JD; Hochman T; Lepor H
    Eur Urol; 2011 Sep; 60(3):548-53. PubMed ID: 21652145
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk factors of positive surgical margin and biochemical recurrence of patients treated with radical prostatectomy: a single-center 10-year report.
    Li K; Li H; Yang Y; Ian LH; Pun WH; Ho SF
    Chin Med J (Engl); 2011 Apr; 124(7):1001-5. PubMed ID: 21542957
    [TBL] [Abstract][Full Text] [Related]  

  • 19. External beam radiotherapy versus radical prostatectomy for clinical stage T1-2 prostate cancer: therapeutic implications of stratification by pretreatment PSA levels and biopsy Gleason scores.
    Kupelian P; Katcher J; Levin H; Zippe C; Suh J; Macklis R; Klein E
    Cancer J Sci Am; 1997; 3(2):78-87. PubMed ID: 9099457
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The results of radical prostatectomy at a community hospital during the prostate specific antigen era.
    Smitt MC; Heltzel M
    Cancer; 1996 Mar; 77(5):928-33. PubMed ID: 8608486
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.